Literature DB >> 24335062

Vision problems are a leading source of modifiable health expenditures.

David B Rein1.   

Abstract

According to recent studies, visual problems represent one of the top contributors to economic health burden in the United States. This burden is divided nearly equally between direct expenditures for the care and treatment of visual problems, and the indirect costs of outcomes caused by low vision, including productivity losses, the cost of care, and incremental nursing home placements. A large amount of academic research is devoted to visual science, the biology of the visual system, and the medical treatment of visual disorders. Compared to the burden, a disproportionate share of this research is devoted to the study of retinal disorders and glaucoma. This is understandable, as research into the retina and optic nerve has the potential to unlock fundamental insights into the nature of sight and visual cognition. However, population visual health and the functionality that depends upon it also may benefit greatly from additional research into areas of prevention, rehabilitation, and adaptation. In addition, comparative research into the benefits of resource allocation across prevention, treatment, and rehabilitative resources could lead to improvements in population health.

Entities:  

Keywords:  cost-effectiveness; economics; resource allocation; review; value of information

Mesh:

Year:  2013        PMID: 24335062     DOI: 10.1167/iovs.13-12818

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  Dendrimers for Ocular Drug Delivery.

Authors:  Michael G Lancina; Hu Yang
Journal:  Can J Chem       Date:  2017-05-11       Impact factor: 1.118

Review 2.  Diabetic Eye Screening: Knowledge and Perspectives from Providers and Patients.

Authors:  Yao Liu; Rebecca Swearingen
Journal:  Curr Diab Rep       Date:  2017-08-31       Impact factor: 4.810

Review 3.  Contribution of the Nurses' Health Study to the Epidemiology of Cataract, Age-Related Macular Degeneration, and Glaucoma.

Authors:  Jae H Kang; Juan Wu; Eunyoung Cho; Soshiro Ogata; Paul Jacques; Allen Taylor; Chung-Jung Chiu; Janey L Wiggs; Johanna M Seddon; Susan E Hankinson; Debra A Schaumberg; Louis R Pasquale
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

Review 4.  Mental distress in patients with cerebral visual injury assessed with the german brief symptom inventory.

Authors:  Carolin Gall; Doreen Brösel; Gabriele Helga Franke
Journal:  Front Aging Neurosci       Date:  2015-05-04       Impact factor: 5.750

5.  Commentary: "Mental Distress in Patients with Cerebral Visual Injury Assessed with the German Brief Symptom Inventory".

Authors:  Ashley Craig
Journal:  Front Aging Neurosci       Date:  2015-06-29       Impact factor: 5.750

6.  Effect of reduced visual acuity on precision of two-dimensional tracing movements.

Authors:  Dmitry Domkin; Hans O Richter; Christina Zetterlund; Lars-Olov Lundqvist
Journal:  J Optom       Date:  2015-05-19

7.  Prevalence of Eye Conditions, Utilization of Eye Health Care Services, and Ophthalmic Medications After Entering Residential Aged Care in Australia.

Authors:  Jyoti Khadka; Julie Ratcliffe; Gillian E Caughey; Steve L Wesselingh; Maria C Inacio
Journal:  Transl Vis Sci Technol       Date:  2021-12-01       Impact factor: 3.283

8.  Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration.

Authors:  Murray H Brilliant; Kamyar Vaziri; Thomas B Connor; Stephen G Schwartz; Joseph J Carroll; Catherine A McCarty; Steven J Schrodi; Scott J Hebbring; Krishna S Kishor; Harry W Flynn; Andrew A Moshfeghi; Darius M Moshfeghi; M Elizabeth Fini; Brian S McKay
Journal:  Am J Med       Date:  2015-10-30       Impact factor: 4.965

9.  Effectiveness and safety of topical levodopa in a chick model of myopia.

Authors:  Kate Thomson; Cindy Karouta; Ian Morgan; Tamsin Kelly; Regan Ashby
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.